Nayar Devjit S
Gastroenterology Associates of Central Jersey, Edison, NJ, USA.
Infect Drug Resist. 2018 Jan 31;11:205-211. doi: 10.2147/IDR.S153617. eCollection 2018.
In order to mitigate potential issues with antibiotic resistance in the treatment of patients with infection, the selection of a therapeutic regimen is optimized by being aware of local eradication rates as well as the patient's medication history and previous diagnoses.
This study primarily aimed to calculate the eradication rate of infection in the New York Metropolitan area when using clarithromycin-based triple therapy per the dosing instructions for Omeclamox-Pak. A secondary objective was to determine risk factors for therapeutic failure.
A retrospective analysis was performed on 156 patients treated with clarithromycin-based triple therapy between 2011 and 2017 at a gastroenterology practice in Edison, New Jersey.
The cumulative eradication rate for the intent-to-treat population was 84%, while the per-protocol rate was 86%. No differences were seen in the rates of subgroups defined by demographics or medication history.
Despite evidence and predictions from other sources in the last decade that clarithromycin-based treatments for are becoming less effective, the results of this study support the use of clarithromycin-based triple therapy as a first-line treatment in the New York Metropolitan region.
为了减轻感染患者治疗中抗生素耐药性的潜在问题，通过了解当地根除率以及患者的用药史和既往诊断来优化治疗方案的选择。
本研究主要旨在根据奥克克拉莫克（Omeclamox-Pak）的给药说明，计算使用基于克拉霉素的三联疗法时纽约大都会地区感染的根除率。次要目标是确定治疗失败的危险因素。
对2011年至2017年间在新泽西州爱迪生市一家胃肠病诊所接受基于克拉霉素的三联疗法治疗的156例患者进行回顾性分析。
意向性治疗人群的累积根除率为84%，符合方案人群的根除率为86%。按人口统计学或用药史定义的亚组根除率未见差异。
尽管在过去十年中其他来源有证据和预测表明基于克拉霉素的治疗效果越来越差，但本研究结果支持在纽约大都会地区将基于克拉霉素的三联疗法作为一线治疗方法。
